Influenza A virus H9N2 vaccine - Nanotherapeutics

Drug Profile

Influenza A virus H9N2 vaccine - Nanotherapeutics

Alternative Names: H9N2 vaccine - Nanotherapeutics; Reverse genetic reassortant H9N2 influenza vaccine

Latest Information Update: 25 Oct 2016

Price : $50

At a glance

  • Originator
  • Developer Nanotherapeutics
  • Class Influenza A vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Influenza A virus H9N2 subtype

Most Recent Events

  • 25 Oct 2016 Phase-II clinical trials in Influenza-A virus H9N2 subtype in USA (IM)
  • 30 Sep 2015 No recent reports on development identified - Phase-I/II for Influenza-A virus H9N2 subtype (In volunteers) in USA (IM)
  • 31 May 2012 Baxter completes a phase I/II trial in Influenza-A virus H9N2 subtype (in volunteers) in USA (NCT01320696)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top